Welcome to the second segment of Big Health Talks, where we speak with clinical experts and benefits leaders about trends, challenges, and solutions in mental health care and the emerging field of digital therapeutics (DTx).
In this episode, Gabriela Perez, Chief Commercial Officer at Big Health, is joined by Cody Midlam, Director and Pharmacist Consultant at Willis Towers Watson. They discuss everything you need to know about DTx: the potential market, benefits, and predictions for the coming years.
How big is the potential market for DTx?
Where do you see DTx going in the next 2-3 years?
Who stands to benefit from the expansion of DTx, and how?
Cody is a paid consultant for Big Health.
Sleepio and Daylight are available as an adjunct to usual medical care for insomnia disorder or generalized anxiety disorder, respectively, for adults ages 18 and older, without FDA review under their COVID-19 policy.
DOC-2919 Effective 06/2023
Here’s our latest
Supporting the mental health of your organization amid rising suicide rates
Understand how organizational changes can positively impact and address the growing mental health crisis.
The far-reaching impact of adolescent depression
Understanding what the rising rates of depression among youth mean for your organization — and actionable tasks HR leaders can…
The truth about generalized anxiety disorder
In our third episode of Big Health Talks, two clinical experts discuss the standard of care for anxiety — and…